Acute Myeloid Leukaemia: Global Clinical Trial Landscape (2024)

Acute Myeloid Leukaemia (AML), the second most common leukemia in both adults and children, poses significant challenges with low survival rates. Globally, it affects over 150,000 individuals, with Asia leading in incidence due to factors like Hepatitis B. Understanding genetic mutations like FLT3, NPM1, and CEBPA is crucial for tailored therapies and improved outcomes.

Treatment involves a blend of chemotherapy and targeted drugs, with emerging immunotherapies offering hope for refractory cases. Over 1,000 clinical trials since 2019 demonstrate a global effort, with North America leading. Marketed drugs like gilteritinib and gemtuzumab ozogamicin, alongside promising pipeline drugs, signify progress toward personalized treatment. This shift from standardized chemotherapy to precision medicine represents a brighter future for AML patients.

Learn how the collaboration among researchers, healthcare providers, and pharmaceutical industries holds promise for progress in Acute Myeloid Leukaemia management and care by downloading the report below.